Macrophagic Activation and Immunophenotypic Profile of Patients With Gaucher's Disease
This study has been completed.
Sponsor:
Nantes University Hospital
Information provided by (Responsible Party):
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT01206673
First received: September 21, 2010
Last updated: December 1, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to evaluate macrophaging activity and immunologic profile of patients with Gaucher 's disease. For this, one blood sampling will be performed.
| Condition | Intervention |
|---|---|
|
Patients With Gaucher's Disease |
Other: Blood sampling |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Evaluation of Macrophagic Activation and Immunophenotypic Profile of Patients With Gaucher's Disease. |
Resource links provided by NLM:
Genetics Home Reference related topics:
Chanarin-Dorfman syndrome
cholesteryl ester storage disease
Farber lipogranulomatosis
Gaucher disease
Schindler disease
succinic semialdehyde dehydrogenase deficiency
MedlinePlus related topics:
Gaucher's Disease
U.S. FDA Resources
Further study details as provided by Nantes University Hospital:
Primary Outcome Measures:
- To determine the implication of acquired and inherent immunity in the Gaucher's clinical phenotype at moment of blood sampling [ Designated as safety issue: No ]
Secondary Outcome Measures:
- to find new activity mark for Gaucher's disease by studying macrophagic activation's markers. [ Designated as safety issue: No ]
| Enrollment: | 10 |
| Study Start Date: | December 2009 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Other: Blood sampling
One blood sampling is required for the research
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adults (age equal or above 18.
- Patients with Gaucher 's disease treated in the "Grand Ouest" competence center
- patients affiliated to social security
- Informed consent signed
Exclusion Criteria:
- Children (age<18)
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Nantes University Hospital |
| ClinicalTrials.gov Identifier: | NCT01206673 History of Changes |
| Other Study ID Numbers: | 09/07-I |
| Study First Received: | September 21, 2010 |
| Last Updated: | December 1, 2011 |
| Health Authority: | France: AFSSAPS |
Additional relevant MeSH terms:
|
Gaucher Disease Sphingolipidoses Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Metabolism, Inborn Errors Genetic Diseases, Inborn Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders |
ClinicalTrials.gov processed this record on May 22, 2013